The AI Agent trading platform Mentis recently detected abnormal fluctuations in information flow and market sentiment signals related to the United States, Israel, and Iran. Subsequently, the situation in the Middle East quickly entered a ceasefire negotiation phase, with multiple geopolitical developments being released, attracting market attention.
The platform's trading interface shows that in the early stages of the event's escalation, the Mentis AI Signal had already indicated continuous buying and trend confirmation signals, with the multi-model consensus system (MTS-GPT, MTS-DS, MTS-Q Flash) simultaneously identifying a strengthening market structure. Following this, the BTC price rapidly rose and broke through a key range, validating the market trend with the direction of the AI signals.
Trading records indicate that the AI Agent completed automated trade execution and position management after the signal formation, with account profits increasing in tandem with the market rise, demonstrating the forward-looking judgment capability of event-driven signals in the early stages.
Mentis stated that its AI Agent continuously tracks cross-market information sources, sentiment changes, and event data, constructing a trading closed loop from information discovery → signal analysis → decision support → automated execution, to enhance response efficiency in sudden macro and geopolitical events.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.















Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.